Five Prime Therapeutics, Inc. FPRX
We take great care to ensure that the data presented and summarized in this overview for FIVE PRIME THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in FPRX
Top Purchases
Top Sells
About FPRX
Insider Transactions at FPRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 16
2021
|
Thomas Civik President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
68,971
-100.0%
|
$2,620,898
$38.0 P/Share
|
|
Apr 16
2021
|
Franklin M Berger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
$190,000
$38.0 P/Share
|
|
Apr 16
2021
|
David White Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,423
-100.0%
|
$1,270,074
$38.0 P/Share
|
|
Apr 16
2021
|
David V Smith Executive Vice President & CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
138,947
-100.0%
|
$5,279,986
$38.0 P/Share
|
|
Apr 16
2021
|
David V Smith Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
66,000
+32.2%
|
-
|
|
Apr 16
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,385
-100.0%
|
$90,630
$38.0 P/Share
|
|
Apr 16
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
169,468
-100.0%
|
$6,439,784
$38.0 P/Share
|
|
Apr 16
2021
|
Francis Willard Sarena Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,000
+28.03%
|
-
|
|
Apr 16
2021
|
Helen Louise Collins EVP and Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
135,547
-100.0%
|
$5,150,786
$38.0 P/Share
|
|
Apr 16
2021
|
Helen Louise Collins EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,000
+32.75%
|
-
|
|
Apr 09
2021
|
Thomas Civik President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,088
-13.85%
|
$410,256
$37.94 P/Share
|
|
Apr 06
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Bona fide gift
|
Direct |
14,174
-12.05%
|
-
|
|
Apr 05
2021
|
William R Ringo Director |
SELL
Bona fide gift
|
Direct |
10,000
-100.0%
|
-
|
|
Apr 05
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Bona fide gift
|
Direct |
2,460
-2.05%
|
-
|
|
Apr 01
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Bona fide gift
|
Direct |
3,825
-1.55%
|
-
|
|
Apr 01
2021
|
Francis Willard Sarena Chief Strategy Officer |
BUY
Bona fide gift
|
Indirect |
2,385
+50.0%
|
-
|
|
Mar 31
2021
|
Helen Louise Collins EVP and Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
8,085
-10.41%
|
-
|
|
Feb 28
2021
|
David White Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,461
-4.19%
|
$32,142
$22.23 P/Share
|
|
Feb 26
2021
|
Helen Louise Collins EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,158
-1.47%
|
$25,476
$22.23 P/Share
|
|
Feb 26
2021
|
Francis Willard Sarena Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,158
-0.93%
|
$25,476
$22.23 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders